Compare ESTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | MESO |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Costa Rica | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2018 | N/A |
| Metric | ESTA | MESO |
|---|---|---|
| Price | $70.68 | $17.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $68.29 | $24.00 |
| AVG Volume (30 Days) | ★ 517.5K | 192.5K |
| Earning Date | 11-05-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,973,000.00 | $17,198,000.00 |
| Revenue This Year | $29.25 | $465.44 |
| Revenue Next Year | $24.94 | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.76 | ★ 191.39 |
| 52 Week Low | $26.56 | $9.61 |
| 52 Week High | $73.19 | $22.00 |
| Indicator | ESTA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 63.71 |
| Support Level | $62.77 | $16.43 |
| Resistance Level | $69.69 | $17.65 |
| Average True Range (ATR) | 3.22 | 0.64 |
| MACD | -0.43 | 0.28 |
| Stochastic Oscillator | 77.82 | 93.38 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.